Observational study of cenegermin for the treatment of limbal stem cell deficiency associated with neurotrophic keratopathy

BACKGROUND: Neurotrophic keratopathy (NK) and limbal stem cell deficiency (LSCD) have high morbidity and require aggressive management to prevent permanent vision loss. Cenegermin, a recombinant human nerve growth factor, was approved by the Federal Drug Administration in 2018 for the treatment of N...

Descripción completa

Detalles Bibliográficos
Autores principales: Arboleda, Alejandro, Ta, Christopher N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638689/
https://www.ncbi.nlm.nih.gov/pubmed/36353571
http://dx.doi.org/10.1177/25158414221134598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638689/
https://www.ncbi.nlm.nih.gov/pubmed/36353571
http://dx.doi.org/10.1177/25158414221134598

Ejemplares similares